Is two (antibiotics) better than one?

Minerva Anestesiologica

Volumn 79, Issue 11, 2013, Pages 1300-1305

  Taccone, F S ^a   Donadello, K ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Anti bacterial agents; Combined modality therapy; Sepsis

Indexed keywords

ANTIBIOTIC AGENT; MEROPENEM; MOXIFLOXACIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; ARTICLE; CLINICAL STUDY; HUMAN; MONOTHERAPY; MORTALITY; MULTICENTER STUDY (TOPIC); MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPSIS; SEPTIC SHOCK; SEVERE SEPSIS; CLINICAL TRIAL (TOPIC); DRUG COMBINATION; PRACTICE GUIDELINE; SHOCK, SEPTIC;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; HUMANS; PRACTICE GUIDELINES AS TOPIC; SEPSIS; SHOCK, SEPTIC;

EID: 84892142251     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S et aL Duration of hypotension before administration of effective antimicrobial therapy is the critical determinant. Crit Care Med 2006;34:1589-96. (Pubitemid 43810035)
2. Garnacho-Montero J, Ortiz-Leyba C, Herrera-Melero I, Aldabó- Pallás T, Cayuela-Dominguez A, Marquez-Vacaro JA et al. Mortality and morbidity attributable to inadequate empirical therapy in patients admitted to the ICU with sepsis: A matched cohort study. J Antimicrob Chemother 2008;61:436-41.
3. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM et al. Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013;39:165-228.
4. Kresken M, Körber-Irrgang B, Läuffer J, Decker-Burgard S, Davies T. In vitro activities of ceftobiprole combined with amikacin or levofloxacin against Pseudomonas aeruginosa: Evidence of a synergistic effect using time-kill methodology. Int J Antimicrob Agents 2011;38:70-5.
5. Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med 1986;80(6B): 126-137. (Pubitemid 16036777)
6. Nichols L, Maki DG. The emergence of resistance to betalactam antibiotics during treatment of Pseudomonas aeruginosa lower respiratory tract infections: is combination therapy the solution? Chemioterapia 1985;4:102-9. (Pubitemid 15149491)
7. Johnson SJ, Ernst EJ, Moores KG. Is double coverage of gram-negative organisms necessary? Am J Health Syst Pharm 2011;68:119-24.
8. Tauber SC, Nau R. Immunomodulatory properties of antibiotics. Curr Mol Pharmacol 2008;1:68-79.
9. Paul M, Silbiger I, Grozinsky S, Soares-Weiser K, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactamaminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2006; 1 :CD003344.
10. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in Gramnegative bacteraemia? A meta-analysis. Lancet Infect Dis 2004;4:519-27. (Pubitemid 39077923)
11. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: A meta-analytic/meta- regression study. Crit Care Med 2010;38:1651-64.
12. Brunkhorst FM, Oppert M, Marx G, Bloos F, Ludewig K, Putensen C et aL Effect of empirical treatment with moxifloxacin and meropenem vs. Meropenem on sepsis-related organ dysfunction in patients with severe sepsis: A randomized trial. JAMA 2012;307:2390-9.
13. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S et aL Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-64.
14. Brower RG, Lanken PN, MacIntyre N, Matthay MA, Morris A, Ancukiewicz M et al. Higher versus lower positive end-expiratory pressures in patients with the acute respiratory distress syndrome. N Engl J Med 2004;351:327-36.
15. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C et al. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779-89.
16. Heyland DK, Dodek P, Muscedere J, Day A, Cook D; Canadian Critical Care Trials Group: Randomized trial of combination versus monotherapy for the empiric treatment of suspected ventilator-associated pneumonia. Crit Care Med 2008;36:737-44.
17. Ong DS, Jongerden IP, Buiting AG, Leverstein-van Hall MA, Speelberg B, Kesecioglu J et al. Antibiotic exposure and resistance development in Pseudomonas aeruginosa and Enterobacter species in intensive care units. Crit Care Med. 2011;39:2458-63.
18. Lipman J, Scribante J, Gous AG, Hon H, Tshukutsoane S. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. Antimicrob Agents Chemother 1998;42:2235-9. (Pubitemid 28420356)
19. Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A et aL Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin Infect Dis 2012;55:943-50.
20. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E et aL Treatment Outcome of Bacteremia Due to KPC-Producing Klebsiella pneumoniae: Superiority of Combination Antimicrobial Regimens. Antimicrobial Agents Chemother 2012;56:2108-13.
21. Delannoy PY, Boussekey N, Devos P, Alfandari S, Turbelin C, Chiche A et al. Impact of combination therapy with aminoglycosides on the outcome of ICU-acquired bacteraemias. Eur J Clin Microbiol Infect Dis 2012;31:2293-9.
22. Bliziotis IA, Petrosillo N, Michalopoulos A, Samonis G, Falagas ME. Impact of Definitive Therapy with Beta-Lactam Monotherapy or Combination with an Aminoglycoside or a Quinolone for Pseudomonas aeruginosa Bacteremia. Plos ONE 2011; 6:e26470.
23. Micek ST, Welch EC, Khan J, Pervez M, Doherty JA, Reichley RM et al. Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to gram-negative bacteria: A retrospective analysis. Antimicronial Agents Chemother 2010;54:1742-8.
24. Peña C, Suarez C, Ocampo-Sosa A, Murillas J, Almirante B, Pomar V et al. for the Spanish Network for Research in Infectious Diseases (REIPI). Effect of adequate singledrug vs combination antimicrobial therapy on mortality in pseudomonas aeruginosa bloodstream infections: A post hoc analysis of a prospective cohort. Clin Infect Dis 2013 [Epub ahead of print].
25. Kumar A, Zarychanski R, Light B, Parrillo J, Maki D, Simon D et al. Cooperative antimicrobial therapy of septic shock (CATSS) database research group. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: A propensity-matched analysis. Crit Care Med 2010;38:1773-85.
26. Martin-Loeches I, Lisboa T, Rodriguez A, Putensen C, Annane D, Garnacho-Montero J, Restrepo MI et aL Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 2010;36:612-20.
27. Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of 2002-2006 OPTAMA programs for US hospitals: Focus on gram-negative resistance. Ann Pharmacother 2009;43:220-7.
28. Roberts J, Lipman J. Antibacterial dosing in intensive care: Pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006;45:755-73.
29. Taccone FS, Laterre P-F, Spapen H, Dugernier T, Dellatre I, Layeux B et al. Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock. Crit Care 2010;14:R53.
30. Galvez R, Luengo C, Cornejo R, Kosche J, Romero C, Tobar E et al. Higher than recommended amikacin doses achieve pharmacokinetic targets without associated toxicity. Int J Antimicrob Agents 2011;38:146-51.
31. Rea RS, Capitano B, Bies R, Bigos KL, Smith R, Lee H. Suboptimal aminoglycoside dosing in critically ill patients. Ther Drug Monit 2008;30:674-81.
32. Taccone FS, de Backer D, Laterre PF, Spapen H, Dugernier T, Delattre I et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents 2011;37:531-5.
33. Durante-Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, Bassetti M et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant acinetobacter baumannii: A multicenter, randomized clinical trial. Clin Infect Dis 2013 [Epub ahead of print].